Patients Coming Off Slimming Jabs Put On Weight Far More Rapidly Compared to Those on Conventional Diets

A recent study indicates that patients who come off new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end conventional diet and exercise regimens.

Published data in a major medical journal shows that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month after stopping.

"People buying these treatments must be informed of the danger of rapid rebound weight gain when the therapy is stopped," stated researcher Dr. Susan Jebb.

This pace of regain suggests a reversion to original weight within about a year and a half.

Comparing Therapies

The analysis, which examined 37 of studies involving thousands of patients, contrasted the outcomes of these new drugs with conventional dieting.

Researchers note that people who lose weight through dieting usually have a less rapid weight regain—approximately 0.1 kg a month—post-intervention.

Understanding the Rapid Rebound

Nutrition scientists propose the mode of action of the injections explains the heightened regain.

The injections mimic a body's own chemical called GLP-1, which helps regulate appetite.

"Long-term administration of GLP-1 concentrations far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this medication means hunger is uncontrolled, making overeating a significant risk."

An Ongoing Issue?

The NHS advise the injections for people with obesity-related health risks, alongside prescribed diet and exercise modifications.

A number of clinicians argue that, considering the significant potential of weight regain, the treatment is often life-long.

This view is supported by drug manufacturers, who say that the findings "underscore the long-term nature of obesity," comparing it to managing diseases like hypertension.

User Experiences

Users who have stopped the medication explain a intense resurgence of cravings.

"It felt as if a switch activating and I was suddenly extremely hungry," recalled one woman.

The struggle is compounded if patients have not established sustainable dietary or behavioural changes during treatment.

Widespread Adoption

Survey data show that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.

• Use is greater among females compared to males.
• The 40s and 50s age group shows the greatest usage rates.
• A large proportion access the medications through private healthcare rather than the NHS.

In conclusion, clinicians caution that while these medications are potent tools for shedding pounds, they are not a standalone solution and maintained weight loss hinges on ongoing behavioural management.